9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

KRT8 Human

Cytokeratin 8 Human Recombinant
RCP1202

Product Overview

Name	KRT8 Human
Description	
Cytokeratin 8 Human Recombinant	
Accession (Primary)	P05787
Synonyms	
Keratin type II cytoskeletal 8, Cytokeratin-8, CK-8, Keratin-8, K8, KRT8, CYK8, KO, CK8, K2C8, CARD2.	
Introduction	
Keratin 8 and 18 (K8/18) are the major components of intermediate filament (IF) proteins of simple or single-layered epithelia.	
Source	
Escherichia Coli.	
Physical Appearance	
Sterile Filtered White lyophilized (freeze-dried) powder.	
Formulation	
The protein (1mg/ml) was lyophilized after from a sterile solution containing 30mM Tris-HCl pH-8, 9.5M urea, 2mM DTT, 2mM EDTA and 10mM methylammonium chloride.	
Stability	
Lyophilized KRT8 although stable at room temperature for 3 weeks, should be stored at 2-8°C. Upon reconstitution KRT8 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.	
Purity	
Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.	
Solubility	
It is recommended to reconstitute the lyophilized KRT8 in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.	
References	

1. Title :Role for the PP2A/B56 Phosphatase in Regulating 14-3-3 Release from Cdc25 to Control Mitosis. Publication :Copyright 2006 Elsevier Inc. All rights reserved.Cell, Volume 127, Issue 4 , 759-773, 17 November 2006

doi:10.1016/j.cell.2006.10.035 Link : KRT8 prospec publication 2. Title :Role for the PP2A/B56? Phosphatase in Regulating 14-3-3 Release from Cdc25 to Control Mitosis. Publication : Received 3 May 2006. Revised 23 August 2006. Accepted 9 October 2006. Available online 16 November 2006. Published: November 16, 2006. Link : Cytokeratin 8 prospec publication

Reconstitution to filaments

Performed by mixing equimolar amounts of cytokeratins of type I and type II at concentrations of approx. 0.5 mg/ml, both dissolved in 9.5 M urea buffer (see above). Protofilaments and filament complexes are obtained by dialyzing the resulting polypeptide solution stepwise to a concentration of 4 M urea and then to low salt condition (50 mM NaCl, 2 mM dithiothreitol, 10 mM Tris-HCl, pH 7.4). For immunization purposes, the solution can be further dialyzed against PBS (phosphate buffered saline, e.g. Dulbecco's PBS).

Precautions

KRT8 Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: (P05787)